FDA center for drug evaluation and research (cder) risk evaluation and mitigation strategy (rems) prescriber education innovation development COR: SAM carter
Ended Awarded Last action
- Contract number
- 75F40121F80450
- Awardee
-
The Mitre Corporation UEI DMHDNDCPWUD1 Part of The Mitre Corporation
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $1,007,081
Award facts
- Contract value 100% obligated
- $1,007,081.15 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Silver Spring, MD 20993, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$45 | |
| Supplemental Agreement for work within scope | $7,500 | |
| Original award | $999,626 |
About this award
This delivery order modification to The Mitre Corporation represents a closeout action by the FDA's Center for Drug Evaluation and Research (CDER) to de-obligate remaining funds under a contract focused on Risk Evaluation and Mitigation Strategy (REMS) prescriber education innovation development. The contract, awarded September 29, 2021, with an ultimate completion date of November 30, 2022, carried a ceiling value of approximately $1.01 million under a Cost Plus Fixed Fee pricing structure. The work was performed in Silver Spring, Maryland, with oversight by Contracting Officer's Representative Sam Carter. As a non-profit Federally Funded Research and Development Center (FFRDC) headquartered in McLean, Virginia, Mitre was well-positioned to support FDA's efforts in developing innovative educational strategies for prescriber engagement related to drug risk mitigation requirements. The contract carried no set-aside designation, consistent with Mitre's status as a large non-profit organization.
This closeout modification reflects the conclusion of CDER's procurement for prescriber education innovation support, with the de-obligation of funds marking the contract's final administrative action. Mitre's engagement on this initiative aligns with its extensive portfolio of healthcare modernization and research support services across federal agencies, particularly through its established relationships with Health and Human Services entities. The modification requires three-way cost approval, indicating standard federal closeout procedures for this delivery order vehicle.
Quick answers
Who was awarded contract 75F40121F80450?
75F40121F80450 was awarded to The Mitre Corporation by Food and Drug Administration (Department of Health and Human Services) on September 29, 2021.
How much is contract 75F40121F80450 worth?
The government has obligated $1,007,081 on 75F40121F80450.
Is contract 75F40121F80450 an order under another contract?
Yes. 75F40121F80450 is a delivery order under 75FCMC18D0047, an indefinite delivery contract.
Was contract 75F40121F80450 competed?
The extent of competition for 75F40121F80450 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award